Loading: 100%
Neos Therapeutics, Inc. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 134 (as per Q2 2016)no data available
Sector Drug Manufacturers, HealthcareDrug Manufacturers, Healthcareno data available
Ticker NEOSno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 175,006,257,508,7510,00
datesClosing price (adj.)
13.10.20178.25
11.10.20178.80
04.10.20179.35
27.09.20178.40
20.09.20178.40
13.09.20179.05
06.09.20178.70
30.08.20178.40
23.08.20177.05
16.08.20176.70
09.08.20176.85
02.08.20176.95
26.07.20176.75
19.07.20176.85
12.07.20176.60
05.07.20177.40
27.06.20177.05
20.06.20178.00
13.06.20177.90
06.06.20178.20
30.05.20178.15
23.05.20177.90
16.05.20177.75
09.05.20177.35
02.05.20176.90
25.04.20177.05
18.04.20177.05
11.04.20176.85
04.04.20177.20
28.03.20177.20
21.03.20176.65
14.03.20176.95
07.03.20176.20
28.02.20176.00
21.02.20175.80
14.02.20175.65
07.02.20175.00
31.01.20175.85
24.01.20175.90
17.01.20175.95
10.01.20176.05
03.01.20176.25
27.12.20167.00
19.12.20166.60
12.12.20166.55
05.12.20166.85
28.11.20167.30
21.11.20168.05
14.11.20168.35
07.11.20165.50
31.10.20165.90
24.10.20166.28
17.10.20166.37
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
8.25n/a
Market Capitalisation
in million USD
133n/a
Enterprise Value
in million USD
113n/a
Common Shares Outstanding
as per Jun 30, 2016
16,070,705n/a
Preferred Shares Outstanding
as per Jun 30, 2016
n/a
Average Basic Shares Outstanding
TTM
15,157,587n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 80n/a
Receivables 6n/a
Total Current Assets 92n/a
PP&E 7n/a
Total Assets 118n/a
Accounts Payable 3n/a
Current Debt 2n/a
Total Current Liabilities 17n/a
Long-Term Debt 59n/a
Total Liabilities 77n/a
Total Equity 41n/a
Cash Flow
Depreciation & Amortisation 3n/a
Change in Working Capital 4n/a
Operating Cash Flow -45n/a
Net Change in PP&E and Intangibles -4n/a
Investing Cash Flow -42n/a
Dividends Paid 0n/a
Financing Cash Flow 103n/a
Total Change in Cash 16n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share 2.69n/a
FCF per Share n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value 3.07n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.31n/a
Other Ratios
Current Ratio 545.7%n/a
Liabilities to Equity Ratio 189.2%n/a
Debt to Assets Ratio 51.2%n/a
Profit & Loss StatementP&L data quality: 56% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '13FY '14FY '15
Revenue
1
1
4
Sales & Services Revenue
0
0
0
Financing Revenue
0
0
0
Other Revenue
0
0
0
Cost of revenue
-3
-3
-6
Cost of Goods & Services
0
0
0
Cost of Financing Revenue
0
0
0
Cost of Other Revenue
0
0
0
Gross Profit
-1
-3
-2
Other Operating Income
0
0
0
Operating Expenses
-16
-16
-25
Selling, General & Administrative
-6
-5
-13
Selling & Marketing
0
0
0
General & Administrative
0
0
0
Research & Development
-10
-11
-12
Depreciation & Amortization
0
0
0
Provision For Doubtful Accounts
0
0
0
Other Operating Expense
0
0
0
Operating Income (Loss)
-17
-18
-27
Non-Operating Income (Loss)
-2
-2
-3
Interest Expense, net
-2
-3
-4
Interest Expense
0
0
0
Interest Income
0
0
0
Other Investment Income (Loss)
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
Income (Loss) from Affiliates
0
0
0
Other Non-Operating Income (Loss)
1
1
1
Pretax Income (Loss), Adjusted
-19
-21
-29
Abnormal Gains (Losses)
0
0
-1
Acquired In-Process R&D
0
0
0
Merger / Acquisition Expense
0
0
0
Abnormal Derivatives
0
0
0
Disposal of Assets
0
0
0
Early extinguishment of Debt
0
0
0
Asset Write-Down
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
Sale of Business
0
0
0
Legal Settlement
0
0
0
Restructuring Charges
0
0
0
Sale of and Unrealized Investments
0
0
0
Insurance Settlement
0
0
0
Other Abnormal Items
0
0
0
Pretax Income (Loss)
-19
-21
-31
Income Tax (Expense) Benefit, net
0
0
0
Current Income Tax
0
0
0
Deferred Income Tax
0
0
0
Tax Allowance/Credit
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
Income (Loss) from Continuing Operations
-19
-21
-31
Net Extraordinary Gains (Losses)
23
24
33
Discontinued Operations
23
24
33
XO & Accounting Charges & Other
0
0
0
Income (Loss) Including Minority Interest
4
3
2
Minority Interest
0
0
0
Net Income
4
3
2
Preferred Dividends
-3
-3
-2
Other Adjustments
0
0
0
Net Income Available to Common Shareholders
1
0
0
Remarks
restated on Mar 18, 2016 n/a
calculated values,
restated on Mar 18, 2016 n/a
calculated values,
restated on Mar 18, 2016 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
16
91
Cash & Cash Equivalents
n/a
13
91
Short Term Investments
n/a
3
0
Accounts & Notes Receivable
n/a
0
4
Accounts Receivable, Net
n/a
0
4
Notes Receivable, Net
n/a
0
0
Unbilled Revenues
n/a
0
0
Inventories
n/a
2
3
Raw Materials
n/a
0
0
Work In Process
n/a
0
0
Finished Goods
n/a
0
0
Other Inventory
n/a
0
0
Other Short Term Assets
n/a
0
1
Prepaid Expenses
n/a
0
0
Derivative & Hedging Assets
n/a
0
0
Assets Held-for-Sale
n/a
0
0
Deferred Tax Assets
n/a
0
0
Income Taxes Receivable
n/a
0
0
Discontinued Operations
n/a
0
0
Miscellaneous Short Term Assets
n/a
0
1
Total Current Assets
n/a
19
98
Property, Plant & Equipment, Net
n/a
6
5
Property, Plant & Equipment
n/a
0
0
Accumulated Depreciation
n/a
0
0
Long Term Investments & Receivables
n/a
0
0
Long Term Investments
n/a
0
0
Long Term Marketable Securities
n/a
0
0
Long Term Receivables
n/a
0
0
Other Long Term Assets
n/a
20
19
Intangible Assets
n/a
18
17
Goodwill
n/a
0
0
Other Intangible Assets
n/a
0
0
Prepaid Expense
n/a
0
0
Deferred Tax Assets
n/a
0
0
Derivative & Hedging Assets
n/a
0
0
Prepaid Pension Costs
n/a
0
0
Discontinued Operations
n/a
0
0
Investments in Affiliates
n/a
0
0
Miscellaneous Long Term Assets
n/a
2
2
Total Noncurrent Assets
n/a
26
24
Total Assets
n/a
45
123
Liabilities and owners' equity
Payables & Accruals
n/a
4 3972000
8 7965000
Accounts Payable
n/a
1 1257000
5 4824000
Accrued Taxes
n/a
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
Other Payables & Accruals
n/a
3 2715000
3 3141000
Short Term Debt
n/a
2 1653000
8 7973000
Short Term Borrowings
n/a
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
Other Short Term Liabilities
n/a
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
Total Current Liabilities
n/a
6 5625000
16 15938000
Long Term Debt
n/a
23 23121000
26 26271000
Long Term Borrowings
n/a
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
Other Long Term Liabilities
n/a
5 5117000
2 1927000
Accrued Liabilities
n/a
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
Pensions
n/a
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
5 5117000
2 1927000
Total Noncurrent Liabilities
n/a
28 28238000
28 28198000
Total Liabilities
n/a
34 33863000
44 44136000
Preferred Equity
n/a
90 90149000
0 0
Share Capital & Additional Paid-In Capital
n/a
5 4832000
195 195330000
Common Stock
n/a
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
Other Share Capital
n/a
0 0
0 0
Treasury Stock
n/a
0 0
0 -171000
Retained Earnings
n/a
-84 -83614000
-117 -116785000
Other Equity
n/a
0 0
0 0
Equity Before Minority Interest
n/a
11 11367000
78 78374000
Minority Interest
n/a
0 0
0 0
Total Equity
n/a
11 11367000
78 78374000
Total Liabilities & Equity
n/a
45 45230000
123 122510000
Remarks restated on n/a restated on Mar 18, 2016 n/a restated on Aug 12, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '13FY '14FY '15
Net Income/Starting Line
-19
-21
-31
Net Income
0
0
0
Net Income From Discontinued Operations
0
0
0
Other Adjustments
0
0
0
Depreciation & Amortization
2
3
3
Non-Cash Items
1
1
3
Stock-Based Compensation
0
0
0
Deferred Income Taxes
0
0
0
Other Non-Cash Adjustments
0
0
0
Change in Working Capital
1
0
-1
(Increase) Decrease in Accounts Receivable
0
0
0
(Increase) Decrease in Inventories
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
Increase (Decrease) in Other
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
Cash from Operating Activities
-15
-17
-26
Change in Fixed Assets & Intangibles
-2
-7
-1
Disposition of Fixed Assets & Intangibles
0
0
0
Disposition of Fixed Assets
0
0
0
Disposition of Intangible Assets
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
Purchase of Fixed Assets
0
0
0
Acquisition of Intangible Assets
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
Net Change in Long Term Investment
0
0
0
Decrease in Long Term Investment
0
0
0
Increase in Long Term Investment
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
Net Cash from Divestitures
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
Cash for Joint Ventures
0
0
0
Net Cash from Other Acquisitions
0
0
0
Other Investing Activities
-7
4
3
Net Cash From Discontinued Operations (investing)
0
0
0
Cash from Investing Activities
-10
-2
2
Dividends Paid
0
0
0
Cash From (Repayment of) Debt
8
21
26
Cash From (Repayment of) Short Term Debt, net
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
Repayments of Long Term Debt
0
0
0
Cash From Long Term Debt
0
0
0
Cash From (Repurchase of) Equity
0
0
0
Increase in Capital Stock
0
0
0
Decrease in Capital Stock
0
0
0
Other Financing Activities
6
0
75
Net Cash From Discontinued Operations (financing)
0
0
0
Cash from Financing Activities
13
21
101
Net Cash Before Disc. Operations and FX
-11
1
77
Change in Cash from Disc. Operations and Other
0
0
0
Net Cash Before FX
-11
1
77
Effect of Foreign Exchange Rates
0
0
0
Net Changes in Cash
-11
1
77
Remarks
restated on Mar 18, 2016 n/a
calculated values,
restated on Mar 18, 2016 n/a
calculated values,
restated on Mar 18, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo